Parnell Pharmaceuticals Holdings Ltd
PARN
PARN was delisted on the 30th of December, 2016.
2 hedge funds and large institutions have $181K invested in Parnell Pharmaceuticals Holdings Ltd in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 15 closing their positions.
85% less capital invested
Capital invested by funds: $1.17M → $181K (-$992K)
90% less funds holding
Funds holding: 20 → 2 (-18)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$227K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$102K |
| 3 |
BlackRock
New York
|
-$63K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$25K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$15K |
PARN Hedge Fund Activity: Q1 2017 in Review
2 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Parnell Pharmaceuticals Holdings Ltd (PARN) for Q1 2017, worth a combined $181K — down 85% from $1.17M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PARN and 0 opened new positions — a net loss of 15 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Sabby Management, adding an estimated $2.67K. The largest seller was Endurant Capital Management, exiting entirely with an estimated $227K sold.
- 2 institutional investors held Parnell Pharmaceuticals Holdings Ltd (PARN) as of Q1 2017, down from 20 in Q4 2016.
- Funds reported $181K of Parnell Pharmaceuticals Holdings Ltd stock for Q1 2017, down 85% quarter-over-quarter.
- 0 funds opened new Parnell Pharmaceuticals Holdings Ltd positions in Q1 2017 and 15 closed out, a net change of -15 holders.
- The largest Parnell Pharmaceuticals Holdings Ltd buyer in Q1 2017 was Sabby Management, an estimated $2.67K added.
- The largest Parnell Pharmaceuticals Holdings Ltd seller in Q1 2017 was Endurant Capital Management, an estimated $227K sold.
Based on aggregated 13F filings for Q1 2017.